WINNIPEG, MANITOBA - Kane Biotech Inc. announced in a press release the issuance of Patent No. 7,597,895 entitled “Signal peptides, nucleic acid molecules and methods for treatment of caries” by the US Patent and Trademark Office.
This is the third patent to be issued protecting Kane Biotech’s CSP (Competence Stimulating Peptide) technology.
This patent claims a composition such as toothpaste, mouthwash, a food additive or chewing gum containing Kane’s CSP analogue peptide called E2 and an additional analogue and/or a monoclonal antibody, antibiotic or antioxidant.
The two previously issued US patents (6,923,962 & 7,556,807) claim isolated as well as synthetic CSP, and a method of preventing and treating dental plaque associated conditions such as dental cavities and periodontal disease using analogues of CSP in oral care formulations.
Dr. Dennis Cvitkovitch (Dental Research Institute, University of Toronto), discoverer of CSP in Streptococcus mutans, demonstrated the ability of CSP analogue peptides to inhibit dental cavities-associated streptococcal biofilm (plaque) formation.
“We have demonstrated a significant synergistic inhibitory effect of combining E2 with selected antimicrobials on dental cavities-associated Streptococci, including S. mutans,” stated Dr. Sri Madhyastha, vice president, Research and Chief Scientific Officer of Kane Biotech.
“This shows that an oral care product containing E2 analogue with either an antibody or antibiotic will be more effective than using the analogue alone in preventing dental cavities,” he added.
Kane Biotech is a biotechnology company engaged in the development of products to prevent and remove biofilms.
